DNDi @ASTMH 2026



Find us at
BOOTH #707
where we are sharing a space with the Medicines for Malaria Venture!

bit.ly/4zsrvWW

November 18-22, 2026
Gaylord National Harbor, Maryland, USA

DNDi
Best Science for the Most Neglected

SYMPOSIA

SYMPOSIUM 2

Transforming VL care: new evidence, oral treatment innovation and pathways to elimination

Thursday, November 19, 8:00 AM – 9:45 AM
Potomac A (Ballroom level)

- **Fabiana Alves, DNDi, Switzerland – Chair**
- Jain Saurabh, World Health Organization, Switzerland
- Srinivasa Rao, Novartis, California, USA
- Shyam Sundar, Banaras Hindu University, India
- Eleni Ayele, Gondar University Hospital, Ethiopia
- Isra Cruz, Instituto de Salud Carlos III, Spain
- **Gláucia Cota, DNDi, Brazil**

SYMPOSIUM 57

Advancing clinical guidelines for Chagas disease worldwide: insights from endemic and non-endemic regions

Friday, November 20, 9:00 AM – 10:45 AM
Potomac C (Ballroom level)

- Clara Crespillo Andújar, Ramón y Cajal Hospital Madrid, Spain – **Co-chair**
- Crystal Y Zheng, Tulane University School of Medicine, Louisiana, USA – **Co-chair**
- João Carlos Pinto Dias, Fundação Oswaldo Cruz, Brazil
- Jaime Altcheh, Hospital de Niños Dr. Ricardo Gutiérrez, Argentina
- Eva Clark, Baylor College of Medicine, Houston, USA
- Pau Bosch, Unitat de Salut Internacional Vall d'Hebron-Drassanes, Spain
- **María-Jesús Pinazo Delgado, DNDi, Brazil**

SCIENTIFIC SESSIONS

SCIENTIFIC SESSION 25

Kinetoplastida and other opportunistic and anaerobic protozoa: Diagnosis and new detection tools

Thursday, November 19, 11:15 AM – 1:00 PM
National Harbor 10/11 (National Harbor Level)

Predicting relapse in visceral leishmaniasis: Novel insights from an individual patient data meta-analysis

- **James Wilson,** IDDO, University of Oxford, UK

SCIENTIFIC SESSION 101

Measures for control and elimination of neglected tropical diseases I

Saturday, November 21, 09:00 AM – 10:45 AM
Maryland A (Ballroom level)

Defining visceral leishmaniasis transmission hotspots in Kenya to guide targeted elimination strategies

- **Paul Kibati,** Amref Health Africa, Kenya

SCIENTIFIC SESSION 103

Kinetoplastida and other opportunistic and anaerobic protozoa: Epidemiology

Saturday, November 21, 09:00 AM – 10:45 AM
Maryland A (Ballroom level)

Time from symptom onset to treatment initiation in visceral leishmaniasis in Brazil, 2007-2023: A national registry-based study

- **Prabin Dahal,** IDDO, University of Oxford, UK

SCIENTIFIC SESSION 110

American committee on clinical tropical medicine and travelers' health (ACCTMTH) Symposium II: Global access to drugs for neglected tropical diseases

Saturday, November 21, 11:15 AM – 1:00 PM
Potomac B (Ballroom level)

Needs-based R&D and access for neglected patients

- **Craig Tipple,** DNDi, Switzerland

SCIENTIFIC SESSION 115

Measures for control and elimination of neglected tropical diseases II

Saturday, November 21, 11:15 AM – 1:00 PM
Maryland C (Ballroom level)

Beyond the thorn: Knowledge gaps, persistent myths and healthcare system barriers affecting mycetoma care in Turkana County, Kenya

- **Alice Sinkeet,** African Institute for Health & Development, Kenya

Prevalence and geographic distribution of mycetoma in Ethiopia: Findings from a community-based cross-sectional survey

- **Dereje Bedane Hunde,** Bahir Dar University, Ethiopia

POSTERS

POSTER SESSION C

Saturday, November 21, 1:00 PM – 2:45 PM
Prince George's Exhibition Hall A (Atrium level) – Poster hall

#7225 - Community engagement in the acceptability of acoziborole, a new single dose, oral treatment for *gambiense* human African trypanosomiasis in the Northern and Southern Ubangi provinces of DRC

#7226 - Access to fexinidazole, a new oral treatment against *rhodesiense* human African trypanosomiasis in Eastern and Southern Africa

#7227 - Efficacy and safety of LXE408, a novel oral treatment candidate for visceral leishmaniasis: Results from a Phase II study in Ethiopia (NCT05957978)

#7228 - Transforming treatment of VL: a proof-of-concept study of LXE408, a novel oral treatment for visceral leishmaniasis, in India

#7229 - Safety of acoziborole in seropositive but parasitologically unconfirmed *gambiense* human African trypanosomiasis: Results from a multicentre randomized double-blind placebo-controlled trial



Side event

DNDi NEW STRATEGIC PLAN 2027-2031 @ASTMH

Join DNDi at ASTMH 2026 for an interactive session featuring our disease heads and R&D experts as we unveil our new Strategic Plan.

We invite ASTMH attendees to join the Drugs for Neglected Diseases initiative (DNDi) on Thursday, November 19 from 6:45 PM – 8:45 PM for a presentation and open dialogue on DNDi's new strategic plan and implementation roadmap over the next five years.

Hear directly from DNDi's scientific and R&D leaders across several areas in our portfolio, including: leishmaniasis, dengue discovery, pandemic preparedness, Chagas, and fungal diseases. This interactive session will include roundtable discussions where participants can connect directly with DNDi experts, ask questions, and exchange ideas on the future of neglected disease R&D.

We hope to see you there, hear your ideas, and explore how we can work together to drive innovation and impact for neglected diseases!

Gaylord National Resort & Convention Center
Room: Potomac 6
National Harbor, Maryland
Thursday, November 19
6:45 PM – 8:45 PM

Light bites and drinks will be provided.

This is not a ticketed event, but **we kindly ask that you register with the QR if you plan to attend.**

bit.ly/4zt6VFY

Photo credits: Brent Stirton-DNDi; Karel Prinsloo-DNDi

DNDi
Best Science for the Most Neglected